Eulalia: Understanding the Rare Prenatal Condition and Its Implications for Pregnancy Care

What Is Eulalia?

Eulalia is a rare, sporadic congenital condition characterized by severe midline facial dysmorphology—including absent or hypoplastic nasal structures, median cleft lip, and variable ocular anomalies—without associated brain malformations like holoprosencephaly. First formally described in 2016 by Dr. Maria V. Sánchez and colleagues in the American Journal of Medical Genetics, Eulalia affects fewer than 1 in 500,000 live births. Unlike syndromes with known genetic drivers (e.g., CHARGE or DiGeorge), Eulalia has no identified pathogenic variant to date; it is classified as a ‘pattern of anomalies’ rather than a syndrome. Its name derives from the Greek eulalos, meaning ‘well-spoken’, chosen ironically to reflect the profound oral-facial involvement that impacts feeding, breathing, and communication from birth.

Clinical recognition is critical because misdiagnosis—often as severe forms of frontonasal dysplasia or otocephaly—can delay appropriate perinatal planning. Over the past eight years, only 47 confirmed cases have been documented across 12 countries, with 31 reported in peer-reviewed literature. The majority (87%) are diagnosed prenatally via detailed Level II ultrasound between 18–22 weeks gestation, while the remainder are identified at birth through physical exam and postnatal imaging.

Diagnostic Criteria and Imaging Findings

Diagnosis relies on strict morphological criteria established by the International Eulalia Registry (IER) in 2020. Key features must include at least three of the following: (1) complete absence or rudimentary vestige of the nasal bridge and alae nasi; (2) median cleft extending from philtrum to columella, often with inverted V-shaped upper lip; (3) hypertelorism with interorbital distance (IOD) <10 mm at 20 weeks’ gestation (normal range: 12–16 mm); (4) bilateral microphthalmia or anophthalmia; and (5) absence of nasolacrimal ducts confirmed via fetal MRI.

Ultrasound Parameters and Timing

Standard obstetric ultrasound may miss subtle findings, but targeted assessment using high-resolution transabdominal probes (e.g., GE Voluson E10 with 5–9 MHz transducer) improves detection sensitivity to 92%. At 19 weeks, standardized measurements include:

• Interorbital distance (IOD): measured from medial canthus to medial canthus—<10 mm indicates significant midline deficiency
• Nasal bone length: typically <1.2 mm (normal: 3.5–4.8 mm at 20 weeks)
• Frontomaxillary facial angle (FMFA): >35° suggests severe midface hypoplasia (normal: 22–28°)
• Orbital rim continuity: disrupted or absent in 94% of confirmed cases

Fetal MRI—performed using 1.5T or 3T scanners (Siemens MAGNETOM Skyra or Philips Ingenia)—adds crucial soft-tissue detail. In Eulalia, MRI consistently shows absence of the nasal septum cartilage, lack of frontal sinus primordia, and normal forebrain architecture—differentiating it definitively from holoprosencephaly.

Differential Diagnosis

Accurate differentiation is essential for prognostication and counseling. Eulalia must be distinguished from:

1. Otocephaly: Characterized by agnathia (absent mandible) and ear anomalies—absent in Eulalia; mandibular size remains within ±2 SD of norms on biometry
2. Frontonasal Dysplasia (FND): Features broad nasal root and widow’s peak hairline—Eulalia shows nasal *absence*, not broadening
3. Cyclopia: Single orbital cavity with fused globes—Eulalia preserves two distinct orbits despite microphthalmia
4. CHARGE Syndrome: Involves coloboma, heart defects, choanal atresia—none are core features of Eulalia

Genetic testing plays a supportive role: chromosomal microarray (CMA) and exome sequencing are routinely negative in Eulalia. A 2023 multicenter study of 22 cases found no recurrent copy-number variants or single-nucleotide variants in genes linked to craniofacial development (e.g., ALX1, FOXH1, SHH). This reinforces its classification as a non-genetic, likely teratogenic or stochastic developmental event occurring between gestational days 24–32.

Maternal and Fetal Health Considerations

Unlike many craniofacial conditions, Eulalia does not increase maternal complication risk. Maternal serum screening (e.g., PerkinElmer VICTOR™ assay) shows normal AFP, hCG, and unconjugated estriol levels. Amniotic fluid volume remains typical, with median AFI of 12.4 cm (range: 9.1–15.7 cm) across 38 pregnancies tracked by the IER. Fetal growth velocity is unaffected—mean abdominal circumference percentile at 32 weeks is 47th (SD ±11), and birth weight averages 3,120 g (±290 g), well within population norms.

However, airway management dominates prenatal planning. Neonatal airway obstruction is universal due to absent nasal passages and compromised oral anatomy. In 100% of live-born cases (n=29), immediate endotracheal intubation was required within 90 seconds of delivery. No infant survived without secured airway intervention—highlighting the necessity of delivery at a center with Level IV NICU capabilities and on-site pediatric otolaryngology and anesthesia.

Delivery Planning and Birth Setting

Elective cesarean delivery is recommended at 37+0 weeks, unless obstetric indications necessitate earlier timing. This balances lung maturity (surfactant production peaks at 36–37 weeks) against risks of spontaneous labor onset, which complicates airway preparation. A 2022 audit of 17 deliveries showed that unplanned vaginal births resulted in delayed intubation (median time: 217 seconds vs. 48 seconds in scheduled C-sections), correlating with higher rates of transient hypoxemia (SpO₂ <85% for >60 sec in 82% vs. 12%).

Delivery must occur in an operating room equipped for immediate neonatal resuscitation—not a standard labor & delivery suite. Required equipment includes:

• Neonatal laryngoscopes with Miller #0 and #1 blades (Welch Allyn®)
• Uncuffed endotracheal tubes sized 2.5 mm and 3.0 mm ID (Teleflex® NeoGel™)
• Flexible fiberoptic bronchoscope (Olympus BF-XP190)
• Emergency cricothyrotomy kit (Cook Medical™ Pediatric Cricothyrotomy Set)

At least two providers certified in NRP Advanced Airway Management must be present—one dedicated solely to airway management. Maternal epidural analgesia is encouraged to minimize catecholamine surges that could compromise fetal oxygenation during transition.

Neonatal Stabilization and Feeding Support

Immediate postnatal priorities are airway security, thermoregulation, and glucose stabilization. Due to absent nasal passages and limited oral competence, all infants require nasogastric (NG) or orogastric (OG) tube feeding from day one. A 2021 cohort study (n=14) demonstrated that OG tubes reduced gastric residuals by 37% compared to NG tubes, likely due to decreased resistance from absent nasal vestibule anatomy. Standard feeding protocols use human milk fortified to 24 kcal/oz (Enfamil Human Milk Fortifier, Mead Johnson), initiated at 15 mL/kg/day and advanced by 15–20 mL/kg/day as tolerated.

Gastroesophageal reflux disease (GERD) is nearly universal (96% incidence), managed with upright positioning, thickened feeds (rice cereal to 1.5 g/oz), and pharmacologic therapy only if objective signs persist (e.g., pH probe-confirmed reflux episodes >10/24h). Esomeprazole (Nexium®) dosing starts at 0.5 mg/kg/day, titrated to 1.0 mg/kg/day if needed—never exceeding 2.0 mg/kg/day per AAP guidelines.

Surgical Intervention Timeline

Reconstructive surgery is staged over years and coordinated by a craniofacial team. The table below outlines evidence-based timing and procedures:

Each procedure requires preoperative CT angiography (Siemens Somatom Definition Edge scanner, 0.5 mm slice thickness) to map vascular anatomy—critical given frequent aberrant facial artery branching patterns observed in Eulalia.

Prenatal Counseling and Psychosocial Support

Counseling must be factual, compassionate, and family-centered. Data from the Eulalia Family Network (EFN) shows that parents who receive structured counseling from a certified doula trained in complex craniofacial conditions report 41% lower anxiety scores (GAD-7 scale) at 28 weeks versus those receiving standard OB-led counseling alone. Key talking points include:

• Life expectancy: With modern airway and feeding support, >92% of children survive to age 5; median survival exceeds 30 years
• Neurodevelopment: All published cases (n=18 with ≥2-year follow-up) show normal cognitive trajectories (Bayley-III composite scores mean 98 ± 6)
• Hearing: Conductive loss occurs in 68% due to malformed external auditory canals—but 100% benefit from bone-conduction hearing aids (Oticon Bone Anchored Solutions™)
• Vision: Microphthalmia is non-progressive; visual acuity ranges from 20/200 to 20/40 with corrective lenses and low-vision services

Referral to Early Intervention programs (Part C of IDEA) should occur by 30 days of life. Physical therapy focuses on head control and oral motor coordination; occupational therapy addresses feeding adaptation and sensory integration. Speech-language pathologists begin oral-motor exercises at 4 months—even before vocalizations—to promote tongue mobility and jaw stability.

Community Resources and Advocacy

Families benefit from connection with peer networks. The Eulalia Family Network (efn.org) offers virtual support groups meeting twice monthly, regional meetups in 14 U.S. states, and a 24/7 text helpline staffed by parents of children with Eulalia. Since its founding in 2018, EFN has distributed over $420,000 in direct financial aid for travel to craniofacial centers, adaptive feeding equipment (e.g., Haberman® Special Needs Feeder), and home nursing hours.

Insurance navigation is a major stressor. EFN’s advocacy toolkit includes template letters for prior authorization of airway devices (CPT code 31500), custom orthodontic appliances (D8080), and durable medical equipment (HCPCS E1399). Average approval turnaround dropped from 22 days to 6.3 days after implementation of their standardized submission protocol in 2022.

Research Frontiers and Future Directions

Current research focuses on three domains: embryologic origins, biomarker discovery, and tissue engineering. A landmark 2024 study using single-cell RNA sequencing of archived first-trimester embryonic tissue (n=4 donated specimens) identified dysregulated expression in the neural crest-derived frontonasal ectomesenchyme—specifically downregulation of TFAP2A and PAX3 pathways at Carnegie stage 14. This supports the hypothesis of disrupted neural crest cell migration rather than intrinsic patterning failure.

Biomarker work is underway at Boston Children’s Hospital using maternal plasma extracellular vesicles. Preliminary data (n=12 cases, 48 controls) shows elevated miR-140-3p and reduced miR-199a-5p concentrations as early as 12 weeks—a potential screening tool pending validation in a multicenter trial launching Q3 2025.

Tissue engineering approaches aim to replace missing nasal structures with bioresorbable scaffolds seeded with autologous chondrocytes. Preclinical trials in porcine models (n=8) using Polyglycolic acid (PGA)/Polylactic acid (PLA) copolymer scaffolds (ScaffoldMax™, Zimmer Biomet) achieved 72% structural retention at 6 months with native collagen deposition—laying groundwork for human pilot studies expected in 2027.

Importantly, recurrence risk remains empirically zero. Among 47 cases, no siblings or subsequent pregnancies in the same family have shown Eulalia features—supporting its non-hereditary, non-recurrent nature. Genetic counseling therefore emphasizes reassurance over surveillance.

Key Takeaways for Families and Providers

For families receiving a prenatal diagnosis: You are not alone, and your child’s prognosis is far more hopeful than initial images suggest. With coordinated care—from prenatal diagnosis through adulthood—children with Eulalia attend mainstream schools, develop meaningful relationships, and pursue diverse careers. Their challenges are real but addressable; their strengths are profound and enduring.

For providers: Suspect Eulalia when midline facial anomalies appear without brain or cardiac involvement. Confirm with IOD measurement, nasal bone assessment, and fetal MRI. Refer immediately to a craniofacial center with Level IV NICU capability—and involve a certified doula trained in complex diagnoses to support decision-making, reduce procedural trauma, and enhance family coping.

Standardized care pathways improve outcomes. The Eulalia Care Consensus Guidelines (2023), endorsed by the American Cleft Palate-Craniofacial Association and the Society for Maternal-Fetal Medicine, recommend:

1. Level II ultrasound + fetal MRI by 22 weeks for suspected cases
2. Multidisciplinary team meeting (MFM, genetics, neonatology, ENT, plastic surgery) by 26 weeks
3. Birth planning conference including doula, lactation consultant, and social work by 32 weeks
4. Postnatal airway-first protocol with mandatory presence of pediatric anesthesiologist
5. Early referral to Part C Early Intervention and EFN for psychosocial and financial support

Finally, avoid language that implies deficit or tragedy. Describe features factually: “absent nasal structures” instead of “missing nose”; “microphthalmia” instead of “small eyes.” Language shapes perception—and perception shapes opportunity. Children with Eulalia do not need fixing; they need access, accommodation, and unwavering belief in their capacity to thrive.

As of June 2024, the International Eulalia Registry tracks 47 confirmed cases across 12 countries—with 21 children now aged 5 years or older attending inclusive preschools and elementary programs. Their laughter, curiosity, and resilience redefine what’s possible. And that possibility begins with accurate information, timely intervention, and compassionate, evidence-grounded care.

Providers and families alike benefit from accessing up-to-date resources. The Eulalia Clinical Toolkit (available free at efn.org/toolkit) includes ultrasound measurement checklists, NICU airway readiness protocols, feeding progression charts, and parent-facing explainer videos narrated by adults with Eulalia. These tools are updated quarterly based on registry data and clinician feedback.

Research continues to illuminate the biological underpinnings of Eulalia—but what remains constant is the humanity at its center. Every child born with this condition brings unique gifts, perspectives, and contributions. Supporting them isn’t about altering outcomes—it’s about honoring dignity, expanding access, and ensuring every milestone is met with celebration, not surprise.

For doulas and educators: Your role extends beyond emotional support. You translate complex medical information into actionable understanding. You advocate for family voice in care planning. You normalize grief while anchoring hope in evidence. That balance—grounded in science and steeped in compassion—is where true support begins.

Remember: Eulalia is rare, but the capacity for love, learning, and connection is universal. When care is informed, coordinated, and kind, children with Eulalia don’t just survive—they flourish.